Indian equity benchmarks advanced on Thursday, driven by gains in heavyweight financials, although a decline in Tata Motors ...

which could disrupt India's pharma industry, leading to higher prices and reduced market share. He urges the Indian government to consider negotiations or a free trade agreement to avoid this crisis.

Warns that Indian pharmaceutical products could become more expensive in the US, reducing their competitiveness in one of the ...

President Donald Trump announced upcoming tariffs on the pharmaceutical industry, without elaborating on specifics. He also ...

The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

Further, India’s pharma industry is also more diversified compared to China’s, with a strong foothold in generics, biotech, and biosimilars. While we discussed the growth of the CDMO industry ...

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

OA affects about 15-20% of the Indian population, especially the elderly, with women being more vulnerable. It leads to joint ...

The industry needs to embrace innovation with technology towards novel drug development to remain relevant in the marketplace.

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. AstraZeneca signed a deal with CSPC Pharma for a cardiac ...